Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Launching of 2D Barcode Implementation on Pharmaceuticals Products and Starting the Pilot Phase in 2018

 
The Ministry of Public health has launched the pilot phase for 2D data Matrix Barcode Implementation on pharmaceutical products in the auditorium of the Ministry in Bir Hassan, under the patronage of Deputy Prime Minister Health Minister Ghassan Hasbani and in the presence of Director General of the Ministry Dr. Walid Ammar, the President of the Lebanese Order of Parmacists Georges Sili, the President of the Syndicate of Pharmaceutical Industries Caroline Abi Karam, the president of the Lebanese Pharmaceutical Importers Association Armond Phares, the President of the Syndicate of Hospital Owners Sleiman Haroun, the President of the Order of Physicians Raymond Sayegh, The Director of the Medical Care Directorate Dr. Joseph El-Helou, WHO representative Dr. Alissar Radi, Director of  E-Health program at the Ministry Lina Abou Mrad, and a number of representatives of hospitals and pharmaceutical industries.

The Director General Dr. Walid ammar explained the strategic frame of the project that comes within the Lebanese pharmaceutical sector reform and improvement plan. This project is achieved by reconsidering the legislations, regulating the registration and pricing of drugs, developing standards and programs to ensure quality in order to provide the patients with a safe quality-assured drug at the right price.

Mrs. Lina Abou Mrad then announced the launch of the implementation of 2D Barcode in 2018, while explaining the requirements of the information system that was lately developed to track the drugs across the supply chain, from manufacturing phase to sale to patients. Mrs Abou Mrad outlined as well the timeline for the implementation phase.

Hasbani

Hasbani said it was a pleasure to launch a new step for a long path of technology implementation to improve the performance of the healthcare sector. “Today we are launching the pilot phase for 2D barcode implementation that aims at ensuring the patient’s access to the safe drug, tracking drugs across the traceability supply chain, controlling illegal drugs and speeding up drugs recall from the Lebanese market and reimbursement of patients affiliated to insurers”, he added.
    1
    ...
ATC Name B/G Ingredients ↑ Dosage Form Price
D03AX RENEBO G ?-sitosterol - 0.25% w/w 0.25% w/w Ointment 456,906 L.L
R01AB08 RINOFLUIMUCIL B Acetylcysteine - 1%, Tuaminoheptane sulfate - 0.5%, Benzalkonium chloride - 0.0125% Solution 419,279 L.L
C05CX REPARIL B Aescine - 20mg 20mg Tablet, sugar coated 510,660 L.L
L01FX18 RYBREVANT BioTech Amivantamab - 350mg 350mg Injectable concentrate for solution 135,818,621 L.L
A11GA01 REDOXON EFF.ORANGE B Ascorbic acid (vit C) - 1g 1g Tablet, effervescent 366,869 L.L
L01AA09 RIBOMUSTIN B Bendamustine HCl - 100mg 100mg Injectable powder for concentrate for solution 31,939,807 L.L
R05DB13 RAPICOD G Butamirate citrate - 0.15% 0.15% Syrup 296,989 L.L
A03CB01 RESTROPINAL PEDIATRIC B Butobarbital - 2mg/ml, Methyl hyoscine nitrate - 0.1mg/ml Drops 197,097 L.L
D05AX52 ROLIP G Calcipotriol - 50mcg, Betamethasone - 0.5mg Ointment 1,574,983 L.L
B05BB01 RINGER'S INJECTION USP G Calcium chloride, 2H2O - 0.033%, Potassium chloride - 0.03%, Sodium chloride - 0.86% Injectable solution 199,957 L.L
B05BB01 RINGER'S INJECTION USP G Calcium chloride, 2H2O - 0.033%, Potassium chloride - 0.03%, Sodium chloride - 0.86% Injectable solution 129,934 L.L
B05BB01 RINGER'S INJECTION USP G Calcium chloride, 2H2O - 0.033%, Potassium chloride - 0.03%, Sodium chloride - 0.86% Injectable solution 205,933 L.L
B05BB01 RINGER'S INJECTION USP G Calcium chloride, 2H2O - 0.033%, Potassium chloride - 0.03%, Sodium chloride - 0.86% Injectable solution 224,565 L.L
B05BB01 R-SOL G Calcium chloride, 2H2O - 0.033%, Potassium chloride - 0.03%, Sodium chloride - 0.86% Injectable solution 205,933 L.L
B05BB01 RINGER'S INJECTION, USP G Calcium chloride, 2H2O - 0.33g/l, Potassium chloride - 0.3g/l, Sodium chloride - 8.6g/l Injectable solution 189,615 L.L
B05BB01 RINGER'S INJECTION, USP G Calcium chloride, 2H2O - 0.33g/l, Potassium chloride - 0.3g/l, Sodium chloride - 8.6g/l Injectable solution 204,554 L.L
B05BB01 RINGER'S INJECTION, USP G Calcium chloride, 2H2O - 0.33g/l, Potassium chloride - 0.3g/l, Sodium chloride - 8.6g/l Injectable solution 154,450 L.L
V03AE01 RESICAL G Calcium Polystyrene Sulphonate - 93.5% w/w 93.5% Powder 1,292,776 L.L
V03AE01 RESINCALCIO G Calcium Polystyrene Sulphonate - 99.75g/100g 99.75% w/w Powder for suspension 1,673,084 L.L
N05AX15 REAGILA G Cariprazine - 6mg 6mg Capsule, hard 6,394,003 L.L
N05AX15 REAGILA G Cariprazine HCl - 1.5mg 1.5mg Capsule, hard 6,394,003 L.L
N05AX15 REAGILA G Cariprazine HCl - 3mg 3mg Capsule, hard 6,394,003 L.L
N05AX15 REAGILA G Cariprazine HCl - 4.5mg 4.5mg Capsule, hard 6,394,003 L.L
J01DB05 ROXIL G Cefadroxil (monohydrate) - 250mg/5ml 250mg/5ml Powder for suspension 459,594 L.L
J01DB05 ROXIL G Cefadroxil (monohydrate) - 500mg 500mg Capsule 869,466 L.L
J01DD04 ROCEPHIN IV B Ceftriaxone (sodium) - 1g 1g Injectable lyophilised powder for solution+diluent 757,927 L.L
J01DD04 ROCEPHIN IM B Ceftriaxone (sodium) - 1g 1g Injectable lyophilised powder for solution+diluent 731,050 L.L
J01DD04 ROCICARE G Ceftriaxone - 1g 1g Injectable powder for solution 9,382,061 L.L
M01AH01 REVCOX G Celecoxib - 200mg 200mg Capsule 506,629 L.L
M01AH01 REVCOX G Celecoxib - 200mg 200mg Capsule 506,629 L.L
    1
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2026